Descriptive Assessment of Coagulopathy Among COVID-19 Patients: Feasibility Data Review

This presentation was given at the Reagan-Udall Foundation and Friends of Cancer Research COVID-19 Diagnostics Evidence Accelerator Parallel Analysis meeting by Noelle Cocoros from Harvard Pilgrim Health Care Institute on behalf of the FDA Sentinel COVID-19 Coagulopathy workgroup. This presentation reviews descriptive feasibility data from select Sentinel Data Partners. These data, focused on thromboembolic outcomes among COVID-19 patients, provide preliminary information for full study implementation.